Advent Buys 50% Stake in Pharmaceutical Contractor InVentiv

  • Private equity deal values InVentiv at about $3.8 billion
  • Drug services company won’t pursue IPO following deal

Advent International Corp. will buy a 50 percent stake in InVentiv Health Inc. that will value the pharmaceutical services firm at $3.8 billion, making Advent a co-owner of the business with Thomas H. Lee Partners.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.